Investigative Ophthalmology & Visual Science Cover Image for Volume 60, Issue 9
July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Visual Field Loss in Patients with Diabetes in the Absence of Clinically-Detectable Vascular Retinopathy
Author Affiliations & Notes
  • Yicheng Bao
    UMKC School of Medicine, Kansas City, Missouri, United States
  • Michael Kass
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, United States
  • Janet McGill
    Department of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis, Missouri, United States
  • Yan Yan
    Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, United States
  • Rithwick Rajagopal
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, United States
  • Footnotes
    Commercial Relationships   Yicheng Bao, None; Michael Kass, None; Janet McGill, None; Yan Yan, None; Rithwick Rajagopal, None
  • Footnotes
    Support  UMKC School of Medicine Sarah Morrison Research Award
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1066. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yicheng Bao, Michael Kass, Janet McGill, Yan Yan, Rithwick Rajagopal; Visual Field Loss in Patients with Diabetes in the Absence of Clinically-Detectable Vascular Retinopathy. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1066.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Neuroretinopathy is increasingly being recognized as an independent cause of vision loss in diabetes. However the temporal relationship of diabetic neuroretinopathy to vascular diabetic retinopathy (DR) is unclear. Visual field loss, as detected by frequency doubling technology (FDT)-based visual perimetry, is a sign of neuroretinopathy and occurs in early stages of DR. Here, we hypothesized that FDT visual field testing could identify patients with diabetic neuroretinopathy in the absence of clinically detectable microvascular DR.

Methods : Data were gathered from the National Health and Nutrition Examination Survey (NHANES) 2005-2008. We included all patients receiving reading center-graded two-field fundus photography and visual field screening by FDT. Patients with self-reported glaucoma, use of glaucoma medications, or determination of glaucoma based on disk features were excluded. Visual fields were screened using a FDT protocol in which participants underwent a 19 subfield suprathreshold test (N-30-5 Humphrey Matrix FDT, Zeiss). Stimuli were presented at an age-adjusted 5%, 2% and 1% probability level in a multi-staged fashion. Patients were grouped based on reading center-based DR assessment. The number of subfields below each probability level was tallied for each patient and compared among groups.

Results : Patients with diabetes but no DR (n=530) were more likely to have ≥1subfielddefects at 5%, 2%, and 1% probability levels than patients without diabetes (n=3243) (41.3% vs 28.6%; 27.4% vs 17.5%; 15.9% vs 9.4%; all p<0.0008). Patients without diabetes had a mean of 1.9 (95% CI: 1.7, 2.2) subfield defects at the 5% probability level, while those with diabetes and no DR had a mean of 3.1 (95% CI: 2.3, 3.9) subfield defects. In participants with diabetes and no DR, a multivariate logistic regression model showed that each additional A1c percentage point was associated with a 19% increase in odds of having ≥1visual subfield defect at the 5% level (OR: 1.19, 95% CI: 1.07,1.33; p=0.0020).

Conclusions : Patients with diabetes have visual field defectsin the absence of detectable DR, suggesting that diabetic neuroretinopathy precedes microvasculopathy. Limitations of this study include the cross-sectional nature of survey data, which lacks temporal data. Longitudinal studies are required to understand the pathogenesis of diabetic neuroretinopathy in relation to classic DR.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×